Top

Diabetologia

Published in:

01-06-2006 | Article

Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets

Authors: J. F. Paulsson, A. Andersson, P. Westermark, G. T. Westermark

Published in: Diabetologia | Issue 6/2006

Abstract

Aims/hypothesis

Islet amyloid is a frequent finding in the islets of Langerhans of individuals with type 2 diabetes. The main amyloid constituent is the beta cell-derived polypeptide hormone islet amyloid polypeptide (IAPP). In general, amyloid refers to an extracellular deposit of a congophilic material, but intracellular amyloid is seen in some beta cells of transgenic mice expressing the gene for human IAPP and in human islets transplanted into nude mice. The aim of this study was to immunohistochemically characterise the intracellular amyloid.

Methods

Antisera against the N- and C-terminal processing sites of proIAPP (which were therefore specific for proIAPP), the C-terminal flanking peptide and mature IAPP were used for immunoelectron microscopy.

Results

Fibrillar aggregates were seen in the halo region of the secretory granules in some beta cells in human IAPP transgenic mice. These aggregates were labelled with proIAPP-specific antisera. Also, proIAPP reactivity was more widespread in the intracellular amyloid-like aggregates in beta cells of transgenic mice than in human islet transplants, in which the intracellular amyloid-like deposits were larger, but the proIAPP labelling was restricted to small spots within the amyloid deposits.

Conclusions/interpretation

We suggest that proIAPP forms the first amyloid fibrils and that this can occur already in the secretory granules of the beta cells. The proIAPP-derived fibrils can act as seed for further amyloid formation, now made up by IAPP. The observed difference between human islet transplants and human IAPP transgenic animals may reflect differences in stages of amyloid development.

Westermark P, Wilander E, Westermark GT, Johnson KH (1987) Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 30:887–892PubMed

Westermark P, Wernstedt C, Wilander E, Sletten K (1986) A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140:827–831PubMedCrossRef

Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF (1988) An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem 263:17243–17246PubMed

Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A (1996) Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227–231PubMedCrossRef

Higham CE, Hull RL, Lawrie L et al (2000) Processing of synthetic pro-islet amyloid polypeptide (proIAPP) ‘amylin’ by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267:4998–5004PubMedCrossRef

Marzban L, Trigo-Gonzalez G, Zhu X et al (2004) Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes 53:141–148PubMedCrossRef

Docherty K, Hutton JC (1983) Carboxypeptidase activity in the insulin secretory granule. FEBS Lett 162:137–141PubMedCrossRef

Marzban L, Soukhatcheva G, Verchere C (2005) Role of carboxypeptidase E in processing of pro-islet amyloid polypeptide in beta-cells. Endocrinology 146:1808–1817PubMedCrossRef

Milgram S, Kho S, Martin G, Mains R, Eipper B (1997) Localization of integral membrane peptidylglycine alpha-amidating monooxygenase in neuroendocrine cells. J Cell Sci 110:695–706PubMed

10.

Roberts AN, Leighton B, Todd JA et al (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 86:9662–9666PubMedCrossRef

11.

Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240–244PubMedCrossRef

12.

Smeekens SP, Montag AG, Thomas G et al (1992) Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA 89:8822–8826PubMedCrossRef

13.

Block MB, Mako M, Steiner DF, Rubenstein AH (1971) Elevated circulating proinsulin levels in insulin-requiring diabetic patients. J Lab Clin Med 78:811–812PubMed

14.

Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY (1995) Proinsulin as a marker for the development of NIDDM in Japanese–American men. Diabetes 44:173–179PubMedCrossRef

15.

Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP (1996) Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest 97:455–460PubMedCrossRef

16.

Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725–1732PubMedCrossRef

17.

Furukawa H, Carroll RJ, Swift HH, Steiner DF (1999) Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes 48:1395–1401PubMedCrossRef

18.

Kayed R, Head E, Thompson J et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489PubMedCrossRef

19.

Lorenzo A, Razzaboni B, Weir G, Yankner B (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756–760PubMedCrossRef

20.

Janson J, Ashley R, Harrison D, McIntyre S, Butler P (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498PubMedCrossRef

21.

Anguiano M, Nowak R, Lansbury PJ (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41:11338–11343PubMedCrossRef

22.

Sparr E, Engel M, Sakharov D et al (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett 577:117–120PubMedCrossRef

23.

Paulsson JF, Westermark GT (2005) Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 54:2117–2125PubMedCrossRef

24.

O’Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC (1994) Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 43:329–336PubMedCrossRef

25.

Westermark GT, Westermark P, Nordin A, Tornelius E, Andersson A (2003) Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice. Ups J Med Sci 108:193–203PubMedCrossRef

26.

Westermark G, Gebre-Medhin S, Steiner DF, Westermark P (2000) Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6:998–1007PubMed

27.

Couce M, Kane LA, O’Brien TD et al (1996) Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094–1101PubMedCrossRef

28.

Janson J, Soeller W, Roche P et al (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288PubMedCrossRef

29.

Westermark P, Eizirik DL, Pipeleers DG, Hellerstrom C, Andersson A (1995) Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 38:543–549PubMedCrossRef

30.

Westermark G, Westermark P, Eizirik DL et al (1999) Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice. Metabolism 48:448–454PubMedCrossRef

31.

Puchtler H, Sweat F (1965) Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 13:693–694PubMed

32.

Westermark P, Benson M, Buxbaum J et al (2002) Amyloid fibril protein nomenclature—2002. Amyloid 9:197–200PubMed

33.

Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379:203–206PubMedCrossRef

34.

Ma Z, Westermark GT (2002) Effects of free fatty acid on polymerization of islet amyloid polypeptide (IAPP) in vitro and on amyloid fibril formation in cultivated isolated islets of transgenic mice overexpressing human IAPP. Mol Med 8:863–868PubMed

35.

MacArthur DL, de Koning EJ, Verbeek JS, Morris JF, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42:219–227CrossRef

36.

Knight JD, Miranker AD (2004) Phospholipid catalysis of diabetic amyloid assembly. J Mol Biol 341:1175–1187PubMedCrossRef

37.

Jayasinghe SA, Langen R (2005) Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44:12113–12119PubMedCrossRef

38.

Janciauskiene S, Eriksson S, Carlemalm E, Ahren B (1997) B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun 236:580–585PubMedCrossRef

39.

Jaikaran E, Nilsson M, Clark A (2004) Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J 377:709–716PubMedCrossRef

40.

Verchere CB, D’Alessio DA, Palmiter RD et al (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496PubMedCrossRef

41.

Hull RL, Shen ZP, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54:2235–2244PubMedCrossRef

42.

Itoh Y, Kawamata Y, Harada M et al (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422:173–176PubMedCrossRef

Title: Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets
Authors: J. F. Paulsson
A. Andersson
P. Westermark
G. T. Westermark
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0206-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 6/2006

The equivocal metabolic response to endotoxaemia in type 2 diabetic and obese ZDF rats

Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans

Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype

Digami too?

Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes

Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page